-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OXI-4503 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OXI-4503 in Refractory Acute Myeloid Leukemia Drug Details: OXI-4503 (combretastatin A1 di-phosphate / CA1P) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1310 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1310 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DB-1310 in Solid TumorDrug Details:The therapeutic candidates are under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1310 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1310 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DB-1310 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:The therapeutic candidates...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1310 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1310 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DB-1310 in Non-Small Cell Lung CancerDrug Details:The therapeutic candidates are under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1310 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1310 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DB-1310 in Human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagitanlimab in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagitanlimab in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagitanlimab in Nasopharyngeal Cancer Drug Details: Tagitanlimab (KLA-167) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ETH-155008 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ETH-155008 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ETH-155008 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:ETH-155008 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagitanlimab in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagitanlimab in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tagitanlimab in Nasopharyngeal CancerDrug Details:Tagitanlimab (KLA-167) is under development for the treatment of  head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Incobotulinumtoxin A in Atrial Fibrillation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Incobotulinumtoxin A in Atrial Fibrillation Drug Details: Incobotulinumtoxin A (Xeomin/Xeomeen/Bocouture) belongs to musculoskeletal system agent....